TCIM
SGNT

TIAA CREF Investment Management’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

TIAA CREF Investment Management’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-108,497
Closed -$1.63M – 3141
2016
Q2 		$1.63M Buy
108,497
+5,009
+5% +$64.3K ﹤0.01% 2249
2016
Q1 		$1.26M Buy
103,488
+29,051
+39% +$407K ﹤0.01% 2340
2015
Q4 		$1.18M Hold
74,437
– – ﹤0.01% 2485
2015
Q3 		$1.14M Sell
74,437
-5,452
-7% -$118K ﹤0.01% 2489
2015
Q2 		$1.94M Sell
79,889
-1,941
-2% -$46.5K ﹤0.01% 2321
2015
Q1 		$1.9M Sell
81,830
-15,200
-16% -$402K ﹤0.01% 2242
2014
Q4 		$2.44M Buy
97,030
+2,009
+2% +$58.9K ﹤0.01% 2112
2014
Q3 		$2.96M Sell
95,021
-3,217
-3% -$87.1K ﹤0.01% 1970
2014
Q2 		$2.54M Buy
98,238
+21,999
+29% +$489K ﹤0.01% 2148
2014
Q1 		$1.78M Sell
76,239
-1,610
-2% -$35.2K ﹤0.01% 2305
2013
Q4 		$1.98M Buy
77,849
+11,638
+18% +$263K ﹤0.01% 2262
2013
Q3 		$1.35M Sell
66,211
-408
-0.6% -$9.08K ﹤0.01% 2430
2013
Q2 		$1.4M Buy
+66,619
New +$1.19M ﹤0.01% 2373

TIAA CREF Investment Management's SGNT Position: Q3 2016 in Review

TIAA CREF Investment Management sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 108,497 shares — an estimated $1.63M sold.

TIAA CREF Investment Management first reported a position in SGNT in Q2 2013 and held it in 13 quarters. The position peaked at $2.96M in Q3 2014. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.

  • TIAA CREF Investment Management reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
  • TIAA CREF Investment Management sold 108,497 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $1.63M.
  • TIAA CREF Investment Management first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 13 quarters.
  • TIAA CREF Investment Management's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $2.96M in Q3 2014.
  • 0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.

Based on TIAA CREF Investment Management's 13F filing for Q3 2016, filed 8 Nov 2016.